Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer

• Main Authors: Ivelina Gueorguieva (Author), Ann Cleverly (Author), Durisala Desaiah (Author), Analia Azaro (Author), Joan Seoane (Author), Irene Braña (Author), Elisabet Sicart (Author), Colin Miles (Author), Michael M Lahn (Author), Malcolm I Mitchell (Author), Jordi Rodon (Author)
• Format: Book
• Published: BioExcel Publishing Ltd, 2016-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunise...